Once-Weekly Insulin as effective as once-daily insulin in type 2 Diabetes: NEJM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-11-25 22:30 GMT | Update On 2020-11-25 22:30 GMT

Researchers have found that Once-weekly treatment with insulin icodec had blood sugar lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes, according to a study published in the New England Journal of Medicine.

It is quite often put to thought that decreased frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analog designed for once-weekly administration that is in development for the treatment of diabetes.

Hence, the authors conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial on a total of 247 participants who all were randomly assigned (1:1) to receive either icodec or glargine. The study aimed to investigate the efficacy and safety of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled while taking metformin with or without a dipeptidyl peptidase 4 inhibitor.

The primary endpoint was the change in glycated hemoglobin level from baseline to week 26. Safety endpoints, including episodes of hypoglycemia and insulin-related adverse events, were also evaluated.

The authors observed the following results from the study-

a. Baseline characteristics were similar in the two groups; the mean baseline glycated hemoglobin level was 8.09% in the icodec group and 7.96% in the glargine group.

b.The estimated mean change from baseline in the glycated hemoglobin level was −1.33 percentage points in the icodec group and −1.15 percentage points in the glargine group, to estimated means of 6.69% and 6.87%, respectively, at week 26.
c.The estimated between-group difference in the change from baseline was −0.18 percentage points.
d.The observed rates of hypoglycemia with the severity of level 2 or level 3 was low.

The authors noted that there was no between-group difference in insulin-related key adverse events, and rates of hypersensitivity and injection-site reactions were low. Also, most of the adverse events were mild, and no serious events were deemed to be related to the trial medications, they added.

Therefore, they concluded that "once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes."

Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Once-Weekly Insulin as effective as once-daily insulin in type 2 Diabetes: NEJM

Similar News

A new diabetes subtype identified in Sub-Saharan Africa and Black Americans, study finds

'Inflammatory' diet during pregnancy may raise child's diabetes type 1 risk: Research

GLP-1 Receptor Agonists Linked to Improved Survival in Older Adults with Cancer and Type 2 Diabetes: Study

Much Awaited Cardiac Safety Data of Tirzepatide Released

Semaglutide and Liraglutide linked to Elevated Risk of Optic Nerve Damage in Seniors With Type 2 Diabetes: JAMA

Study Links High Stress Hyperglycemia Ratio to Diabetic Retinopathy Progression and Post-Surgery Complications

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds

Methylglyoxal Independently Contributes to Liver Fibrosis in Obesity: Study